| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6266423 | Current Opinion in Neurobiology | 2015 | 5 Pages |
â¢We discuss optogenetic and opto-pharmacological strategies for vision restoration.â¢AAQ, an ion channel photoswitch, restores visual responses to blind mice.â¢DENAQ is an improved photoswitch with increased lifetime and light sensitivity.â¢DENAQ selectively photosensitizes blind retinas without affecting healthy retinas.â¢DENAQ and related compounds are potential therapeutics for retinitis pigmentosa.
Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are progressive retinal diseases that result from the death of rod and cone photoreceptors, ultimately leading to blindness. The only currently approved vision restoration treatment employs an implanted retinal 'chip' as a prosthetic device to electrically stimulate retinal neurons that survive after the photoreceptors are gone, thereby restoring light-driven neural signaling to the brain. Alternative strategies have been proposed, which would utilize optogenetic or optopharmacological tools to enable direct optical stimulation of surviving retinal neurons. Here, we review the latest studies evaluating the feasibility of these molecular tools as potential therapeutics for restoring visual function in human blinding disease.
